Paladin Labs JTSX: PLB

Paladin Labs to Acquire Canadian License to Pennsaid

· Issued by Paladin Labs J via CNW
TORONTO and MONTREAL, Aug. 16 /CNW/ - Paladin Labs Inc. (TSX: PLB), a
Canadian speciality pharmaceutical company, has acquired Dimethaid Health Care
Ltd. (DHCL), a subsidiary of Dimethaid Research Inc. (TSX:DMX). DHCL owns the
Canadian license for Pennsaid(R), a lotion approved by Health Canada for the
treatment of symptoms of knee osteoarthritis.
In return for its ownership of DHCL, Dimethaid Research has received an
up-front payment, a share in operating profits above minimum targets and a
long-term supply agreement. "Pennsaid offers a valuable treatment option to
those suffering from osteoarthritis," said Jonathan Ross Goodman, president
and CEO of Paladin Labs. "This is evidenced by the fact that for the first
6 months of 2005, Pennsaid sales increased by 40% versus last year. We expect
that Pennsaid will be an $8-9 million brand in Canada by the end of 2005."
"This is an important transaction for Dimethaid as it provides funding to
implement our business plan without an immediate public market financing that
would be dilutive to our shareholders. While we are giving up a portion of our
Pennsaid Canadian revenue, we will continue to participate in Pennsaid's
future Canadian success," said Dan Chicoine, chairman of Dimethaid. "We will
now continue discussions with a number of pharmaceutical companies interested
in licensing Pennsaid and Pennsaid Plus for the United States."

About Paladin Labs Inc.
Paladin Labs, headquartered in Montreal, Canada, is a leading specialty
pharmaceutical company focused on developing, acquiring or in-licensing
innovative pharmaceutical products for the Canadian market. With this
strategy, a focused national sales team and proven marketing expertise,
Paladin has evolved into one of Canada's leading specialty pharmaceutical
companies. Paladin's shares trade on the Toronto Stock Exchange under the
symbol PLB. For more information about Paladin, please visit the Paladin Web
Site at www.paladinlabs.com.

About Dimethaid Research Inc.
Dimethaid Research Inc. is a publicly traded, Canadian pharmaceutical
company headquartered in Markham, Ontario, with manufacturing facilities in
Varennes, QuDebec and Wanzleben, Germany. The Company develops targeted
therapeutic drugs designed to produce minimal side effects. Dimethaid's two
technology platforms focus on transcellular drug delivery and immune system
regulation. Products are aimed at expanding treatment options in rheumatology,
dermatology, oncology, immunology, and the therapeutic management of chronic
viral infections. For more information, please visit www.dimethaid.com.

This news release may contain forward-looking statements or predictions.
These statements represent our judgement as of this date and are subject to
risks and uncertainties that could cause actual results or events to differ
materially from those expressed in such forward-looking statements. Potential
risks and uncertainties include, without limitation, those associated with
product development, clinical trials, future revenues and profitability, and
obtaining marketing approval and other factors. For additional information on
risks and uncertainties related to the forward-looking statements, investors
should consult the company's ongoing quarterly filings, annual reports and
Annual Information Form and other filings found on SEDAR at www.sedar.com.

%SEDAR: 00002418E

Paladin Labs J on 6ix

Later from Paladin Labs J

All Paladin Labs J news releases